Exelixis | EXEL - Cash And Equivalent


Exelixis reported $304.77M in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 976.45M 19.97M Sep/2026
Agios Pharmaceuticals USD 128.55M 28.9M Sep/2026
Akebia Therapeutics USD 159.25M 3.71M Sep/2026
Amgen USD 13.19B 799M Sep/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Bayer EUR 4.29B 1.44B Jun/2026
BioMarin Pharmaceutical USD 736.01M 138M Sep/2026
Bristol-Myers Squibb USD 9.57B 852M Sep/2026
Cytokinetics USD 203.43M 51.84M Sep/2026
Eisai JPY 245.42B 56.22B Mar/2026
Eli Lilly USD 4.89B 4.07B Sep/2026
Exelixis USD 304.77M 23.33M Sep/2026
Genmab DKK 1.5B 18M Jun/2026
Glaxosmithkline GBP 2.93B 508M Sep/2026
Incyte USD 3.85B 127.8M Sep/2026
Ionis Pharmaceuticals USD 296.3M 53.76M Sep/2026
MacroGenics USD 49.03M 64.88M Sep/2026
Merck USD 9.55B 2.7B Sep/2026
Moderna USD 1.2B 528M Sep/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Neurocrine Biosciences USD 641.5M 309.1M Sep/2026
Novartis USD 8.87B 1.25B Sep/2026
Pfizer USD 1.82B 848M Sep/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Sanofi EUR 6.35B 806M Jun/2026
Takeda JPY 418.53B 42.45B Sep/2026
Ultragenyx Pharmaceutical USD 150M 25M Sep/2026
Xencor USD 59.62M 14.96M Sep/2026